Link to this page
The Drug-Drug Interactions Ontology
Last uploaded:
February 11, 2016
| Id | http://purl.obolibrary.org/obo/dinto_DB01307
http://purl.obolibrary.org/obo/dinto_DB01307
|
|---|---|
| Preferred Name | insulin detemir |
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| prefLabel | insulin detemir
|
|---|---|
| label | insulin detemir
|
| DBSynonym | 29b-[n6-(oxo-tetradecy)-l-lysine]-(1a-21a),(1b-29b)-insulin (human)
|
| ATCCode | A10AE05
|
| Definition | Insulin detemir is a long-acting human insulin analogue used to maintain basal levels of insulin in diabetic individuals. It is produced using recombinant DNA technology in yeast cells. This insulin analogue has a 14-C fatty acid, myristic acid, bound to the lysine amino acid at position B29. The myristoyl side chain increases self-association and albumin binding. This along with slow systemic absorption from the injection site prolongs distribution of the hormone into tissues and results in a long duration of action. Novo Nordisk markets insulin detemir under the trade name Levemir.
|
| has pharmacological target | |
| induces | |
| activates | |
| type | |
| AHFScode | 68:20.08
|
| xref |
PDRhealth:http://www.pdrhealth.com/drugs/rx/rx-mono.aspx?contentFileNam
Drugs.com:http://www.drugs.com/monograph/insulin-detemir.html
National Drug Code Directory:0169-3687-12
PharmGKB:PA164746470
RxList:http://www.rxlist.com/levemir-drug.htm
Wikipedia:http://en.wikipedia.org/wiki/Insulin_detemir
See more
See less
|
| CASRN | 169148-63-4
|
| prefixIRI | obo2:dinto_DB01307
|
| related with | |
| may interact with |
See more
See less
|
| DBBrand |
levemir
levemir flexpen
|
| subClassOf |
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |